BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 [PMID: 36338892 DOI: 10.3748/wjg.v28.i39.5750]
URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5750.htm
Number Citing Articles
1
Jiayang Yu, Yufei Zhang, Chun-Guang Wang, Wei Yang, Fen Chen. Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysisDermatologica Sinica 2025; 43(2): 107 doi: 10.4103/ds.DS-D-24-00059
2
Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim. Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancerThe Korean Journal of Internal Medicine 2025; 40(1): 49 doi: 10.3904/kjim.2024.135
3
Masaya Iwamuro, Sakiko Hiraoka, Motoyuki Otsuka. A case of immune checkpoint inhibitor-associated colitis treated with infliximabOkayama Igakkai Zasshi (Journal of Okayama Medical Association) 2024; 136(2): 69 doi: 10.4044/joma.136.69
4
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerationsFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1122430
5
Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Javier Puente, Laurent Essioux, Corey Carter, Jose Vicente Cardona, Rajat Mohindra, Jarushka Naidoo. Correlation of safety and efficacy of atezolizumab therapy across indicationsJournal for ImmunoTherapy of Cancer 2024; 12(11): e010158 doi: 10.1136/jitc-2024-010158
6
Anas Zaher, Maria Julia Moura Nascimento Santos, Hassan Elsaygh, Stephen J. Peterson, Carolina Colli Cruz, Anusha Shirwaikar Thomas, Yinghong Wang. Management of refractory checkpoint inhibitor-induced colitisExpert Opinion on Drug Safety 2025; : 1 doi: 10.1080/14740338.2025.2496431